Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: Focus on efavirenz and nevirapine

Drug Metabolism Reviews

Volumn 47, Issue 2, 2015, Pages 111-123

  Čolić, Antoinette ^a   Alessandrini, Marco ^b   Pepper, Michael S ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Drug metabolism; Hepatotoxicity; HIV AIDS; Inter ethnic variability; Neurotoxicity

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 2B7; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP2A6 PROTEIN, HUMAN; CYP2B6 PROTEIN, HUMAN; GLUCURONOSYLTRANSFERASE; UGT2B7 PROTEIN, HUMAN;

AFRICA; AFRICAN; ALLELE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; BLACK PERSON; DRUG DETOXIFICATION; ENZYMOLOGY; GENETICS; HIV INFECTIONS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-HIV AGENTS; BENZOXAZINES; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HUMANS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; NEVIRAPINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84932117610     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.982864     Document Type: Review

References (51)

1. Alessandrini M, Asfaha S, Dodgen TM, et al. (2013). Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 45: 253-275.
2. Alessandrini M, Pepper MS. (2014). Priority pharmacogenetics for the African continent: Focus on CYP450. Pharmacogenomics 15: 385-400.
3. Belanger AS, Caron P, Harvey M, et al. (2009). Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 37: 1793-1796.
4. Brown KC, Hosseinipour MC, Hoskins JM, et al. (2012). Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 13:113-121.
5. Ciccacci C, Borgiani P, Ceffa S, et al. (2010). Nevirapine-induced hepatotoxicity and pharmacogenetics: A retrospective study in a population from Mozambique. Pharmacogenomics 11:23-31.
6. Court MH. (2010). Interindividual variability in hepatic drug glucuronidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-224.
7. Dandara C, Swart M, Mpeta B, et al. (2014). Cytochrome P450 pharmacogenetics in African populations: Implications for public health. Expert Opin Drug Metab Toxicol 10:769-785.
8. De Wit E, Delport W, Rugamika CE, et al. (2010). Genome-wide analysis of the structure of the South African coloured population in the Western Cape. Hum Genet 128:145-153.
9. Department of Health (DOH), Republic of South Africa. (2013). The South African antriretroviral treatment guidelines. Available from: http://www.sahivsoc.org/upload/documents/2013%20ART%20GuidelinesShort%20Combined%20FINAL%20draft%20guidelines%2014%20March%202013.pdf [last accessed 16 Apr 2014].
10. Desta Z, Saussele T, Ward B, et al. (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547-558.
11. Di Iulio J, Fayet A, Arab-Alameddine M, et al. (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19:300-309.
12. Elens L, Vandercam B, Yombi JC, et al. (2010). Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 11:1223-1234.
13. Gatanga H, Hayashida T, Tsuchiya K, et al. (2007). Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B66 and 26. Clin Infect Dis 45:1230-1237.
14. Gounden V, Van Niekerk C, Snyman T, George JA. (2010). Presence of the CYP2B6 516G4T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7:32.
15. Gross R, Aplenc R, Tenhave T, et al. (2008). Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 49: 336-337.
16. Guillemette, C. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136-158.
17. Gyamfi MA, Fujieda M, Kiyotani K, et al. (2005). High prevalence of cytochrome P450 2A61A alleles in a black African population of Ghana. Eur J Clin Pharmacol 60:855-857.
18. Haas DW, Bartlett JA, Andersen JW, et al. (2006). Pharmacogenetics of nevirapine-Associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43:783-786.
19. Haas DW, Ribaudo HJ, Kim RB, et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18:2391-2400.
20. Ikediobi O, Aouizerat B, Xiao Y, et al. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 5:265-282.
21. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
22. Ingelman-Sundberg M. (2007). Pharmacogenetics of the P450s. In: Daly A, ed. Drug metabolizing enzymes: Fundamentals, study methods, recent advances and clinical significance. The Biomedical & Life Sciences Collection. London: Henry Stewart Talks Ltd. Available from: http://0-hstalks.com.innopac.up.ac.za/?tBL0091124 [last accessed 28 Oct 2014].
23. Jamshidi Y, Moreton M, Mckeown DA, et al. (2010). Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: Implications for efavirenz dosing in HIV infection. J Antimicrob Chemother 65:2614-2619.
24. Joint United Nations Programme on HIV/AIDS. (2011). UNAIDS World AIDS Day Report 2011. UNAIDS. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216-worldaidsday-report-2011-en.pdf [last accessed 20 Apr 2014].
25. Klein K, Lang T, Saussele T, et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15: 861-873.
26. Kwara A, Lartey M, Sagoe KW, et al. (2009). CYP2B6 (c.516G-4T) and CYP2A6 (9B and/or 17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 67:427-436.
27. Kwara A, Lartey M, Sagoe KW, et al. (2009). CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101-2106.
28. Li J, Menard V, Benish RL, et al. (2012). Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: Implications for HIV/AIDS treatment. Pharmacogenomics 13: 555-570.
29. Mahungu TW, Johnson MA, Owen A, Back DJ. (2009). The impact of pharmacogenetics on HIV therapy. Int J STD AIDS 20: 145-151.
30. Maimbo M, Kiyotani K, Mushiroda T, et al. (2012). CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 68:267-271.
31. Mehlotra RK, Bockarie MJ, Zimmerman PA. (2007). CYP2B6 983T4C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment. Br J Clin Pharmacol 64:391-395.
32. Michaud V, Bar-Magen T, Turgeon J, et al. (2012). The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 64:803-833.
33. Mukonzo JK, Roshammar D, Waako P, et al. (2009). A novel polymorphism in ABCB1 gene, CYP2B66 and sex predict singledose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68:690-699.
34. Murray CJ, Vos T, Lozano R, et al. (2013). Disability-Adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197-2223.
35. Ngaimisi E, Habtewold A, Minzi O, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 8:e67946.
36. Nyakutira C, Roshammar D, Chigutsa E, et al. (2008). High prevalence of the CYP2B6 516G4T (6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64:357-365.
37. Parathyras J, Gebhardt S, Hillermann-Rebello R, et al. (2009). A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 54:261-265.
38. Penzak SR, Kabuye G, Mugyenyi P, et al. (2007). Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 8:86-91.
39. Radloff R, Gras A, Zanger UM, et al. (2013). Novel CYP2B6 enzyme variants in a Rwandese population: Functional characterization and assessment of in silico prediction tools. Hum Mutat 34:725-734.
40. Riska P, Lamson M, MacGregot T, et al. (1999). Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27:895-901.
41. Saeki M, Saito Y, Jinno H, et al. (2004). Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048-1054.
42. Sarfo FS, Zhang Y, Egan D, et al. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 69:491-499.
43. Schoedel KA, Hoffmann EB, Rao Y, et al. (2004). Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615-626.
44. Swart M, Skelton M, Ren Y, et al. (2013). High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 23: 415-427.
45. Swart M, Skelton M, Wonkam A, et al. (2012). CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 Polymorphisms in Two Bantu-Speaking Populations from Cameroon and South Africa: Implications for Global Pharmacogenetics. Curr Pharmacogen Pers Med 10:43-53.
46. Thorn CF, Lamba JK, Lamba V, et al. (2010). PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 20:520-523.
47. Tishkoff SA, Reed FA, Friedlaender FR, et al. (2009). The genetic structure and history of Africans and African Americans. Science 324: 1035-1044.
48. Wang J, Sonnerborg A, Rane A, et al. (2006). Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 16:191-198.
49. Ward BA, Gorski JC, Jones DR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
50. Warnich L, Drogemo ller BI, Pepper MS, et al. (2011). Pharmacogenomic research in South Africa: Lessons learned and future opportunities in the Rainbow Nation. Curr Pharmacogenomics Person Med 9:191-207.
51. Whirl-Carrillo M, McDonagh EM, Herbert JM, et al. (2012). Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414-417.